Gleeson, M; Hawkes, EA; Cunningham, D; Chadwick, N; Counsell, N; Lawrie, A; Jack, A; ... Linch, D; + view all Gleeson, M; Hawkes, EA; Cunningham, D; Chadwick, N; Counsell, N; Lawrie, A; Jack, A; Smith, P; Mouncey, P; Pocock, C; Ardeshna, KM; Radford, J; McMillan, A; Davies, J; Turner, D; Kruger, A; Johnson, PWM; Gambell, J; Linch, D; - view fewer (2016) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. British Journal of Haematology , 175 (4) pp. 668-672. 10.1111/bjh.14287.

Preview

Text Counsell_PMBL manuscript British Journal of Haematology revised.pdf - Accepted Version Download (306kB) | Preview

Abstract

We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item